PE20001495A1 - Derivados de mevinolina - Google Patents
Derivados de mevinolinaInfo
- Publication number
- PE20001495A1 PE20001495A1 PE2000000114A PE0001142000A PE20001495A1 PE 20001495 A1 PE20001495 A1 PE 20001495A1 PE 2000000114 A PE2000000114 A PE 2000000114A PE 0001142000 A PE0001142000 A PE 0001142000A PE 20001495 A1 PE20001495 A1 PE 20001495A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alcoxyl
- mevinoline
- derivatives
- hydroxyalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
SE REFIERE A DERIVADOS DE MEVINOLINA DE FORMULA I, DONDE R1 ES H, ALQUILO C1-C4, ORa; Ra ES H, ALQUILO C1-C6; R2 ES OCOR5; R5 ES ALQUILO C1-C8, CICLOALQUILO C3-C7, OR6, ENTRE OTROS; R6 ES UN O-AMINOACIDO UNIDO A O POR UN CARBONILO, HR7C-COR8; R7 ES H, ALQUILO C1-C4, HETEROALQUILO C1-C4, ENTRE OTROS; R8 ES OH, ALCOXILO C1-C4, NR9R10; R9 Y R10 SON H, ALQUILO C1-C4 O JUNTO CON N FORMAN UN HETEROARILO; R3 ES UNA LACTAMA, PIPERIDILO, AMINO-ALCOHOL, CARBAMATO CICLICO, -CH2-CH(R13)-CH2-CH(R14)-CHR15R16; R13 ES OH, ALCOXILO C1-C6, -O-CO-ALQUILO C1-C6, OCONH-ALQUILO C1-C6; R14 ES OH, ALCOXILO C1-C4, ALQUILO C1-C4, ENTRE OTROS; R15 ES H, ALQUILO C1-C4; R16 ES CONR17R8; UNO DE R17 Y R18 ES H Y EL OTRO ES ALQUILO C1-C6, HIDROXIALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS; R4 ES H, OR19; R19 ES ALQUILO C1-C6, HIDROXIALQUILO C1-C6, ALCOXILO C1-C4, ENTRE OTROS. UN COMPUESTO PREFERIDO ES (S)-(3R,8aR)-8-{(S)-2-[(1R,5R)-3-(4-HIDROXI-3-METOXI-BENCIL)-4-METILCARBAMOILMETIL-2-OXO[1,3]OXAZINAN-6-IL]-ETIL}-7-METIL-3-METIL-1,2,3,7,8,8a-HEXAHIDRO-NAFTALEN-1-ILESTER DE ACIDO (S)-2-METILBUTIRICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS UN INMUNOSUPRESOR, INMUNOMODULADOR, ANTIINFLAMATORIO. EL COMPUESTO I ES UN INHIBIDOR DE LA ADHESION DEL ANTIGENO LFA-1 A LA MOLECULA 1 DE ADHESION INTERCELULAR ICAM-1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9903546A GB9903546D0 (en) | 1999-02-16 | 1999-02-16 | Organic compounds |
GB9927880A GB9927880D0 (en) | 1999-11-25 | 1999-11-25 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20001495A1 true PE20001495A1 (es) | 2001-01-12 |
Family
ID=26315146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000114A PE20001495A1 (es) | 1999-02-16 | 2000-02-14 | Derivados de mevinolina |
Country Status (17)
Country | Link |
---|---|
US (2) | US20020037895A1 (es) |
EP (1) | EP1154988B1 (es) |
JP (1) | JP4167806B2 (es) |
CN (1) | CN1229335C (es) |
AR (1) | AR022588A1 (es) |
AT (1) | ATE273272T1 (es) |
AU (1) | AU763357B2 (es) |
BR (1) | BR0008292A (es) |
CA (1) | CA2361841C (es) |
CO (1) | CO5140104A1 (es) |
DE (1) | DE60012888T2 (es) |
DK (1) | DK1154988T3 (es) |
ES (1) | ES2226802T3 (es) |
PE (1) | PE20001495A1 (es) |
PT (1) | PT1154988E (es) |
SI (1) | SI1154988T1 (es) |
WO (1) | WO2000048989A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2758037B2 (ja) * | 1989-08-04 | 1998-05-25 | 株式会社アマダ | タレットパンチプレスの金型インデックス装置 |
US6110922A (en) | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US6878700B1 (en) | 1998-12-29 | 2005-04-12 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
NZ523445A (en) | 2000-06-29 | 2004-10-29 | Abbott Lab | Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
CA2422820A1 (en) * | 2000-09-19 | 2002-03-28 | Novimmune S.A. | Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
US6974815B2 (en) | 2002-10-11 | 2005-12-13 | Bristol-Myers Squibb Company | Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents |
PT1682537E (pt) | 2003-11-05 | 2012-06-20 | Sarcode Bioscience Inc | Moduladores de adesão celular |
JP4710612B2 (ja) * | 2003-12-26 | 2011-06-29 | 日本新薬株式会社 | オクタヒドロナフタレン誘導体及び医薬 |
MXPA06014354A (es) * | 2004-06-09 | 2007-02-19 | Genentech Inc | Metodo para tratar granuloma anular o sarcoide. |
EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
TW200616634A (en) | 2004-10-01 | 2006-06-01 | Bristol Myers Squibb Co | Crystalline forms and process for preparing spiro-hydantoin compounds |
US7186727B2 (en) | 2004-12-14 | 2007-03-06 | Bristol-Myers Squibb Company | Pyridyl-substituted spiro-hydantoin compounds and use thereof |
ES2830024T3 (es) | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
CN102617533B (zh) * | 2011-02-01 | 2014-08-27 | 北京北大维信生物科技有限公司 | 一种从红曲中分离的化合物、其制备方法及用途 |
US10736871B2 (en) | 2015-04-01 | 2020-08-11 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
US10822357B2 (en) | 2015-08-28 | 2020-11-03 | Sekisui Medical Co., Ltd. | Benzyl compound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678806A (en) | 1986-09-02 | 1987-07-07 | Merck & Co., Inc. | Prodrugs of antihypercholesterolemic compounds |
US4820850A (en) | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US5021451A (en) * | 1988-11-14 | 1991-06-04 | Hoffman-La Roche Inc. | Method for inhibiting hyperproliferative diseases |
DE69008277D1 (de) * | 1989-08-31 | 1994-05-26 | Merck & Co Inc | 7-Subsituierte HMG-CoA-Reduktase-Inhibitoren. |
NZ250609A (en) * | 1992-12-28 | 1995-07-26 | Sankyo Co | Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments |
US5393893A (en) | 1993-11-08 | 1995-02-28 | Apotex, Inc. | Process for producing simvastatin and analogs thereof |
CZ127198A3 (cs) * | 1995-11-02 | 1998-12-16 | Warner-Lambert Company | Způsob regulace koncentrace lipidů a farmaceutická kompozice pro tento způsob |
US5763653A (en) | 1997-03-13 | 1998-06-09 | Ranbaxy Laboratories, Ltd. | Key intermediates in the manufacture of simvastatin |
US5763646A (en) | 1997-03-13 | 1998-06-09 | Ranbaxy Laboratories, Ltd. | Process for manufacturing simvastatin from lovastatin or mevinolinic acid |
IL131044A (en) | 1997-01-28 | 2003-07-31 | Plus Chemicals Bv | Process for the production of semi synthetic statins via novel intermediates |
DE69839399T2 (de) * | 1997-08-28 | 2009-05-20 | Novartis Ag | Lymphozyten funktion antigen-1 antagonisten |
-
2000
- 2000-02-09 CO CO00008363A patent/CO5140104A1/es unknown
- 2000-02-14 DE DE60012888T patent/DE60012888T2/de not_active Expired - Fee Related
- 2000-02-14 CN CNB008038171A patent/CN1229335C/zh not_active Expired - Fee Related
- 2000-02-14 JP JP2000599730A patent/JP4167806B2/ja not_active Expired - Fee Related
- 2000-02-14 SI SI200030511T patent/SI1154988T1/xx unknown
- 2000-02-14 CA CA002361841A patent/CA2361841C/en not_active Expired - Fee Related
- 2000-02-14 AR ARP000100626A patent/AR022588A1/es unknown
- 2000-02-14 AU AU38040/00A patent/AU763357B2/en not_active Ceased
- 2000-02-14 EP EP00916832A patent/EP1154988B1/en not_active Expired - Lifetime
- 2000-02-14 WO PCT/EP2000/001191 patent/WO2000048989A1/en active IP Right Grant
- 2000-02-14 AT AT00916832T patent/ATE273272T1/de not_active IP Right Cessation
- 2000-02-14 PT PT00916832T patent/PT1154988E/pt unknown
- 2000-02-14 DK DK00916832T patent/DK1154988T3/da active
- 2000-02-14 ES ES00916832T patent/ES2226802T3/es not_active Expired - Lifetime
- 2000-02-14 BR BR0008292-9A patent/BR0008292A/pt not_active Application Discontinuation
- 2000-02-14 PE PE2000000114A patent/PE20001495A1/es not_active Application Discontinuation
-
2001
- 2001-08-13 US US09/928,593 patent/US20020037895A1/en not_active Abandoned
-
2002
- 2002-07-11 US US10/192,888 patent/US6818638B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1229335C (zh) | 2005-11-30 |
AR022588A1 (es) | 2002-09-04 |
BR0008292A (pt) | 2001-11-06 |
EP1154988B1 (en) | 2004-08-11 |
US20020037895A1 (en) | 2002-03-28 |
CN1340044A (zh) | 2002-03-13 |
AU3804000A (en) | 2000-09-04 |
EP1154988A1 (en) | 2001-11-21 |
CA2361841A1 (en) | 2000-08-24 |
CA2361841C (en) | 2008-12-02 |
DK1154988T3 (da) | 2004-11-22 |
US6818638B2 (en) | 2004-11-16 |
US20030087903A1 (en) | 2003-05-08 |
PT1154988E (pt) | 2004-12-31 |
SI1154988T1 (en) | 2005-02-28 |
ATE273272T1 (de) | 2004-08-15 |
DE60012888D1 (de) | 2004-09-16 |
JP4167806B2 (ja) | 2008-10-22 |
AU763357B2 (en) | 2003-07-17 |
ES2226802T3 (es) | 2005-04-01 |
JP2002537284A (ja) | 2002-11-05 |
CO5140104A1 (es) | 2002-03-22 |
DE60012888T2 (de) | 2005-08-18 |
WO2000048989A1 (en) | 2000-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20001495A1 (es) | Derivados de mevinolina | |
AR034244A1 (es) | Derivados de 4-aminopiperidina y su uso como medicamento | |
PE20020707A1 (es) | Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c | |
CO5690561A2 (es) | Administracion oral de acido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil]fosfonico y derivados | |
HUP0302962A2 (hu) | Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása | |
HUP0303037A2 (hu) | Alzheimer-kór kezelésére alkalmas vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
MY133992A (en) | Muscarinic antagonists | |
TR199601032A2 (tr) | Matris metalloprotaz önleyicileri. | |
NO175259C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive triazolo-1,4-diazepinforbindelser | |
PE20020500A1 (es) | Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas | |
BRPI0312882B8 (pt) | derivados de pleuromutilina e composição farmacêutica | |
KR920703628A (ko) | 티로트로핀-방출 호르몬(trh)의 프로드러그 유도체 | |
NZ233970A (en) | N-heteroaryl-purin-6-amines and pharmaceutical compositions | |
BR0309558A (pt) | Derivados de quinazolina e medicamentos | |
KR900014388A (ko) | 에세롤린의 카보네이트 유도체, 이의 제조방법 및 약제로서의 용도 | |
PE20020294A1 (es) | Derivados de pirrolidina como inhibidores de la enzima conversor de endotelina | |
PE20050050A1 (es) | Derivados de indolilo | |
AR041678A1 (es) | Formas cristalinas de clorhidrato de donepezil | |
ATE226934T1 (de) | Ester und amide als pla2-inhibitoren | |
ATE12933T1 (de) | N-substituierte azaheterocyclische carbonsaeure und ihre ester. | |
FR2631339B1 (fr) | Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique | |
DE69132707T2 (de) | N-Acyldipeptide, und pharmazeutische Präparate davon | |
AR027578A1 (es) | Derivados de indano | |
AR021970A1 (es) | Inhibidores de proteasas | |
KR950032158A (ko) | 신규의 티아진 또는 티오모폴린 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |